Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation

Leukemia volume 20, pages 1168–1169 (2006)Cite this article

Chronic myeloproliferative diseases (MPDs) are clonal hematopoietic stem cell disorders characterized by cytokine hypersensitivity and normal cell maturation. Recently, the constitutively active mutant of Janus kinase 2 (JAK2), V617F, has been found in MPDs.1, 2, 3, 4 JAK2 located at 9p24 is a member of a family of tyrosine kinases involved in cytokine receptor signaling.5 Development of acute leukemia is not common but one of the forms of terminal stage in MPDs. However, its additional molecular abnormalities have not been fully characterized.

In acute leukemia transformed from MPDs (N=7), we examined FLT3, N-RAS and p53 gene mutations, which were frequently found in de novo acute myeloid leukemia (AML) in addition to JAK2 gene mutation. Samples of mononuclear cells were obtained from peripheral blood or bone marrow cells stored in Nagoya University. All patients gave informed consent for study in accordance with the approval of the institutional ethics committee. We examined the JAK2 mutation by reverse transcription-PCR using the following primers: JAK2F: 5′-AAAGGCGTACGAAGAGAAGTAGGAG-3′ and JAK2R: 5′-TCACTAAGTTTGATGAAAGGAGGAT-3′. The amplified 416-bp fragment was subjected to sequence analysis and restriction enzyme digestion with BsaXI. Mutations of FLT3, N-RAS and p53 genes were also analyzed as previously described.6

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.

    Article  CAS  Google Scholar 

  2. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.

    Article  CAS  Google Scholar 

  3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.

    Article  CAS  Google Scholar 

  4. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.

    Article  CAS  Google Scholar 

  5. Vainchenker W, Constantinescu SN . A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology (Am Soc Hematol Educ Program) 2005; 195–200.

  6. Nakano Y, Kiyoi H, Miyawaki S, Asou N, Ohno R, Saito H et al. Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene. Br J Haematol 1999; 104: 659–664.

    Article  CAS  Google Scholar 

  7. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377–3379.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan

    M Suzuki, A Abe, M Murata, T Kinoshita & T Naoe

  2. Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan

    H Kiyoi

  3. Department of Hematology, Yokkaichi Municipal Hospital, Mie, Japan

    Y Ito

  4. Department of Hematology and Oncology, JA Aichi Showa Hospital, Kohnan, Japan

    K Shimada & Y Morishita

Authors
  1. M Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Kiyoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Murata
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y Morishita
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Kinoshita
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. T Naoe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Suzuki, M., Abe, A., Kiyoi, H. et al. Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation. Leukemia 20, 1168–1169 (2006). https://doi.org/10.1038/sj.leu.2404186

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404186

This article is cited by

Search

Advanced search

Quick links